Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ANUJA JHINGRAN and PATRICIA J EIFEL.
ANUJA JHINGRAN
Connection Strength
4.833
PATRICIA J EIFEL
  1. Vaginal motion and bladder and rectal volumes during pelvic intensity-modulated radiation therapy after hysterectomy. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):256-62.
    View in: PubMed
    Score: 0.394
  2. Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy. Int J Radiat Oncol Biol Phys. 2003 Aug 01; 56(5):1366-72.
    View in: PubMed
    Score: 0.238
  3. Perioperative and postoperative complications of intracavitary radiation for FIGO stage I-III carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 2000 Mar 15; 46(5):1177-83.
    View in: PubMed
    Score: 0.188
  4. Impact of treatment year on survival and adverse effects in patients with cervical cancer and paraortic lymph node metastases treated with definitive extended-field radiation therapy. Pract Radiat Oncol. 2017 May - Jun; 7(3):e165-e173.
    View in: PubMed
    Score: 0.147
  5. Survival outcomes for patients with stage IVB vulvar cancer with grossly positive pelvic lymph nodes: time to reconsider the FIGO staging system? Gynecol Oncol. 2015 Feb; 136(2):269-73.
    View in: PubMed
    Score: 0.131
  6. Morbid obesity as an independent risk factor for disease-specific mortality in women with cervical cancer. Obstet Gynecol. 2014 Dec; 124(6):1098-1104.
    View in: PubMed
    Score: 0.130
  7. Prospective study of symptom assessment among patients with cervical cancer during concurrent chemoradiotherapy with weekly cisplatin or every-3-week cisplatin and 5-fluorouracil. Int J Gynecol Cancer. 2013 Oct; 23(8):1520-7.
    View in: PubMed
    Score: 0.120
  8. Involved-field radiation therapy for locoregionally recurrent ovarian cancer. Gynecol Oncol. 2013 Aug; 130(2):300-5.
    View in: PubMed
    Score: 0.117
  9. A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium. Gynecol Oncol. 2013 May; 129(2):304-9.
    View in: PubMed
    Score: 0.115
  10. Pilot study of a computed tomography-compatible shielded intracavitary brachytherapy applicator for treatment of cervical cancer. Pract Radiat Oncol. 2013 Apr-Jun; 3(2):115-23.
    View in: PubMed
    Score: 0.109
  11. Intensity modulated radiation therapy for definitive treatment of paraortic relapse in patients with endometrial cancer. Pract Radiat Oncol. 2013 Jan-Mar; 3(1):e21-e28.
    View in: PubMed
    Score: 0.109
  12. Anatomic distribution of [(18)F] fluorodeoxyglucose-avid lymph nodes in patients with cervical cancer. Pract Radiat Oncol. 2013 Jan-Mar; 3(1):45-53.
    View in: PubMed
    Score: 0.108
  13. Novel technique for simulation and external beam treatment planning for obese patients. Pract Radiat Oncol. 2011 Jul-Sep; 1(3):152-5.
    View in: PubMed
    Score: 0.102
  14. Concurrent chemoradiation in the routine management of patients with cervical cancer: does marital status matter? Int J Gynecol Cancer. 2009 Aug; 19(6):1107-12.
    View in: PubMed
    Score: 0.090
  15. Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation. Gynecol Oncol. 2009 Oct; 115(1):6-11.
    View in: PubMed
    Score: 0.090
  16. Patterns of regional recurrence after definitive radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys. 2010 Apr; 76(5):1396-403.
    View in: PubMed
    Score: 0.090
  17. Predictive value of a proposed subclassification of stages I and II cervical cancer based on clinical tumor diameter. Int J Gynecol Cancer. 2009 Jan; 19(1):2-7.
    View in: PubMed
    Score: 0.087
  18. Cervix regression and motion during the course of external beam chemoradiation for cervical cancer. Int J Radiat Oncol Biol Phys. 2009 Jan 01; 73(1):235-41.
    View in: PubMed
    Score: 0.083
  19. Comparison of treatment tolerance and outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy in a prospective randomized trial or with standard treatment. Int J Radiat Oncol Biol Phys. 2008 Jan 01; 70(1):118-25.
    View in: PubMed
    Score: 0.079
  20. Primary adenocarcinoma of the vagina not associated with diethylstilbestrol (DES) exposure. Gynecol Oncol. 2007 May; 105(2):470-4.
    View in: PubMed
    Score: 0.076
  21. Time course and outcome of central recurrence after radiation therapy for carcinoma of the cervix. Int J Gynecol Cancer. 2006 May-Jun; 16(3):1106-11.
    View in: PubMed
    Score: 0.072
  22. A three-dimensional computed tomography-assisted Monte Carlo evaluation of ovoid shielding on the dose to the bladder and rectum in intracavitary radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys. 2005 Oct 01; 63(2):615-21.
    View in: PubMed
    Score: 0.069
  23. Intensity-modulated radiation therapy after hysterectomy: comparison with conventional treatment and sensitivity of the normal-tissue-sparing effect to margin size. Int J Radiat Oncol Biol Phys. 2005 Jul 15; 62(4):1117-24.
    View in: PubMed
    Score: 0.068
  24. Comparison between CT-based volumetric calculations and ICRU reference-point estimates of radiation doses delivered to bladder and rectum during intracavitary radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys. 2005 May 01; 62(1):131-7.
    View in: PubMed
    Score: 0.067
  25. Definitive radiation therapy for squamous cell carcinoma of the vagina. Int J Radiat Oncol Biol Phys. 2005 May 01; 62(1):138-47.
    View in: PubMed
    Score: 0.067
  26. Feasibility of dose escalation using intensity-modulated radiotherapy in posthysterectomy cervical carcinoma. Int J Radiat Oncol Biol Phys. 2005 Mar 15; 61(4):1062-70.
    View in: PubMed
    Score: 0.067
  27. Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence. Gynecol Oncol. 2004 Apr; 93(1):27-33.
    View in: PubMed
    Score: 0.062
  28. Malignant mixed M?llerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys. 2004 Mar 01; 58(3):786-96.
    View in: PubMed
    Score: 0.062
  29. Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapy. Brachytherapy. 2024 Mar-Apr; 23(2):123-135.
    View in: PubMed
    Score: 0.061
  30. Management and long-term clinical outcomes of patients with stage IVA cervical cancer with bladder involvement. Gynecol Oncol. 2024 Jan; 180:24-34.
    View in: PubMed
    Score: 0.061
  31. Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring. Cancer Cell. 2023 11 13; 41(11):1945-1962.e11.
    View in: PubMed
    Score: 0.060
  32. Patient Reported Outcomes for Women Undergoing Definitive Chemoradiation for Gynecologic Cancer: A Prospective Clinical Trial. Pract Radiat Oncol. 2023 Nov-Dec; 13(6):e538-e546.
    View in: PubMed
    Score: 0.060
  33. Circulating neutrophils and tumor-associated myeloid cells function as a powerful biomarker for response to chemoradiation in locally advanced cervical cancer. Clin Transl Radiat Oncol. 2023 Mar; 39:100578.
    View in: PubMed
    Score: 0.057
  34. Metagenomes of rectal swabs in larger, advanced stage cervical cancers have enhanced mucus degrading functionalities and distinct taxonomic structure. BMC Cancer. 2022 Sep 01; 22(1):945.
    View in: PubMed
    Score: 0.056
  35. Longitudinal Changes in Bone Mineral Measurements Inside and Outside Radiation Fields Used for Cervical Cancer Treatment. Pract Radiat Oncol. 2022 Sep-Oct; 12(5):e423-e433.
    View in: PubMed
    Score: 0.054
  36. Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers. Cancer Immunol Res. 2022 02; 10(2):259-271.
    View in: PubMed
    Score: 0.053
  37. Long-term survival following definitive radiation therapy for recurrence or oligometastases in gynecological malignancies: A landmark analysis. Gynecol Oncol. 2022 03; 164(3):550-557.
    View in: PubMed
    Score: 0.053
  38. Use of Specific Duodenal Dose Constraints During Treatment Planning Reduces Toxicity After Definitive Paraaortic Radiation Therapy for Cervical Cancer. Pract Radiat Oncol. 2022 May-Jun; 12(3):e207-e215.
    View in: PubMed
    Score: 0.053
  39. A prospective study of the adaptive changes in the gut microbiome during standard-of-care chemoradiotherapy for gynecologic cancers. PLoS One. 2021; 16(3):e0247905.
    View in: PubMed
    Score: 0.050
  40. NRG Oncology/RTOG Consensus Guidelines for Delineation of Clinical Target Volume for Intensity Modulated Pelvic Radiation Therapy in Postoperative Treatment of Endometrial and Cervical Cancer: An Update. Int J Radiat Oncol Biol Phys. 2021 02 01; 109(2):413-424.
    View in: PubMed
    Score: 0.049
  41. A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation. Support Care Cancer. 2021 Jan; 29(1):213-222.
    View in: PubMed
    Score: 0.047
  42. Clinical utility and value contribution of an MRI-positive line marker for image-guided brachytherapy in gynecologic malignancies. Brachytherapy. 2020 May - Jun; 19(3):305-315.
    View in: PubMed
    Score: 0.047
  43. Pelvic fractures and changes in bone mineral density after radiotherapy for cervical, endometrial, and vaginal cancer: A prospective study of 239 women. Cancer. 2020 06 01; 126(11):2607-2613.
    View in: PubMed
    Score: 0.047
  44. Microbial Diversity and Composition Is Associated with Patient-Reported Toxicity during Chemoradiation Therapy for Cervical Cancer. Int J Radiat Oncol Biol Phys. 2020 05 01; 107(1):163-171.
    View in: PubMed
    Score: 0.047
  45. Developing an intraoperative 3T MRI-guided brachytherapy program within a diagnostic imaging suite: Methods, process workflow, and value-based analysis. Brachytherapy. 2020 Jul - Aug; 19(4):427-437.
    View in: PubMed
    Score: 0.046
  46. Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer. Gynecol Oncol. 2019 07; 154(1):22-28.
    View in: PubMed
    Score: 0.044
  47. Quantifying institutional resource utilization of adjuvant brachytherapy and intensity-modulated radiation therapy for endometrial cancer via time-driven activity-based costing. Brachytherapy. 2019 Jul - Aug; 18(4):445-452.
    View in: PubMed
    Score: 0.044
  48. Kinetics of Intratumoral Immune Cell Activation During Chemoradiation for Cervical Cancer. Int J Radiat Oncol Biol Phys. 2018 11 01; 102(3):593-600.
    View in: PubMed
    Score: 0.042
  49. Role of Radiation Therapy in the Multidisciplinary Management of Uterine Carcinosarcoma. Int J Gynecol Cancer. 2018 01; 28(1):114-121.
    View in: PubMed
    Score: 0.040
  50. Outcomes and patterns of relapse after definitive radiation therapy for oligometastatic cervical cancer. Gynecol Oncol. 2018 01; 148(1):132-138.
    View in: PubMed
    Score: 0.040
  51. Patterns of recurrence and survival in neuroendocrine cervical cancer. Gynecol Oncol. 2016 Dec; 143(3):552-557.
    View in: PubMed
    Score: 0.037
  52. Comparison of Computed Tomography- and Magnetic Resonance Imaging-based Clinical Target Volume Contours at Brachytherapy for?Cervical Cancer. Int J Radiat Oncol Biol Phys. 2016 11 15; 96(4):793-800.
    View in: PubMed
    Score: 0.037
  53. Consensus Recommendations for Radiation Therapy Contouring and Treatment of?Vulvar?Carcinoma. Int J Radiat Oncol Biol Phys. 2016 07 15; 95(4):1191-200.
    View in: PubMed
    Score: 0.036
  54. Management of nodal recurrences of endometrial cancer with IMRT. Gynecol Oncol. 2015 Oct; 139(1):40-6.
    View in: PubMed
    Score: 0.034
  55. Isolated port-site metastases after minimally invasive hysterectomy for endometrial cancer: outcomes of patients treated with radiotherapy. Int J Gynecol Cancer. 2015 Jun; 25(5):869-74.
    View in: PubMed
    Score: 0.034
  56. High-Grade Cervical Dysplasia following Radiation Therapy for Invasive Cervical Cancer: A Report of Four Cases. Case Rep Oncol. 2015 May-Aug; 8(2):217-21.
    View in: PubMed
    Score: 0.034
  57. Optimizing packing contrast for MRI-based intracavitary brachytherapy planning for cervical cancer. Brachytherapy. 2015 May-Jun; 14(3):385-9.
    View in: PubMed
    Score: 0.033
  58. Dosimetric predictors of duodenal toxicity after intensity modulated radiation therapy for treatment of the para-aortic nodes in gynecologic cancer. Int J Radiat Oncol Biol Phys. 2014 Feb 01; 88(2):357-62.
    View in: PubMed
    Score: 0.031
  59. Galectin-7 levels predict radiation response in squamous cell carcinoma of the cervix. Gynecol Oncol. 2013 Dec; 131(3):645-9.
    View in: PubMed
    Score: 0.029
  60. Anatomic distribution of fluorodeoxyglucose-avid para-aortic lymph nodes in patients with cervical cancer. Int J Radiat Oncol Biol Phys. 2013 Mar 15; 85(4):1045-50.
    View in: PubMed
    Score: 0.029
  61. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part III: low-dose-rate and pulsed-dose-rate brachytherapy. Brachytherapy. 2012 Jan-Feb; 11(1):53-7.
    View in: PubMed
    Score: 0.027
  62. Role of definitive radiation therapy in carcinoma of unknown primary in the abdomen and pelvis. Int J Radiat Oncol Biol Phys. 2012 Apr 01; 82(5):2012-7.
    View in: PubMed
    Score: 0.026
  63. Expression of nuclear transcription factor kappa B in locally advanced human cervical cancer treated with definitive chemoradiation. Int J Radiat Oncol Biol Phys. 2010 Dec 01; 78(5):1331-6.
    View in: PubMed
    Score: 0.024
  64. Pelvic fractures after radiotherapy for cervical cancer: implications for survivors. Cancer. 2010 Feb 01; 116(3):625-30.
    View in: PubMed
    Score: 0.023
  65. Gene expression changes in cervical squamous cell carcinoma after initiation of chemoradiation and correlation with clinical outcome. Int J Radiat Oncol Biol Phys. 2008 May 01; 71(1):226-36.
    View in: PubMed
    Score: 0.021
  66. Uterine cancers. J Natl Compr Canc Netw. 2006 May; 4(5):438-62.
    View in: PubMed
    Score: 0.018
  67. Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol. 2005 Oct 20; 23(30):7428-36.
    View in: PubMed
    Score: 0.017
  68. Dosimetric evaluation of the Fletcher-Williamson ovoid for pulsed-dose-rate brachytherapy: a Monte Carlo study. Phys Med Biol. 2005 Nov 07; 50(21):5075-87.
    View in: PubMed
    Score: 0.017
  69. Heterogeneity of stage IIIA endometrial carcinomas: implications for adjuvant therapy. Int J Gynecol Cancer. 2005 May-Jun; 15(3):510-6.
    View in: PubMed
    Score: 0.017
  70. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol. 2003 Dec; 91(3):463-9.
    View in: PubMed
    Score: 0.015
  71. Innovations in the treatment of invasive cervical cancer. Cancer. 2003 Nov 01; 98(9 Suppl):2052-63.
    View in: PubMed
    Score: 0.015
  72. The role of radiation therapy in preventing regional recurrences of invasive squamous cell carcinoma of the vulva. Int J Radiat Oncol Biol Phys. 2003 Oct 01; 57(2):409-18.
    View in: PubMed
    Score: 0.015
  73. Utility of lymphangiography in the prediction of lymph node metastases in patients with cervical cancer. Int J Gynecol Cancer. 2002 Nov-Dec; 12(6):755-9.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.